Pirenzepine
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.044.739 |
Chemical and physical data | |
Formula | C19H21N5O2 |
Molar mass | 351.410 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
Pirenzepine (Gastrozepin), an M1 selective antagonist, is used in the treatment of peptic ulcers, as it reduces gastric acid secretion and reduces muscle spasm. It is in a class of drugs known as muscarinic receptor antagonists - acetylcholine being the neurotransmitter of the parasympathetic nervous system which initiates the rest-and-digest state (as opposed to fight-or-flight), resulting in an increase in gastric motility and digestion; whereas pirenzepine would inhibit these actions and cause decreased gastric motility leading to delayed gastric emptying and constipation.[1] It has no effects on the brain and spinal cord as it cannot diffuse through the blood–brain barrier.
Pirenzepine has been investigated for use in myopia control.[2][3]
It promotes the homodimerization or oligomerisation of M1 receptors.[4]
See also
References
- ↑ Stolerman IP (2 August 2010). Encyclopedia of Psychopharmacology. Springer. p. 811. ISBN 978-3-540-68698-9. Retrieved 26 June 2013.
- ↑ Czepita D (2005). "[Fundamentals of modern treatment of myopia]". Annales Academiae Medicae Stetinensis. 51 (2): 5–9. PMID 16519089.
- ↑ Walline, Jeffrey J.; Lindsley, Kristina B.; Vedula, S. Swaroop; Cotter, Susan A.; Mutti, Donald O.; Ng, Sueko M.; Twelker, J. Daniel (13 January 2020). "Interventions to slow progression of myopia in children". The Cochrane Database of Systematic Reviews. 1 (9): CD004916. doi:10.1002/14651858.CD004916.pub4. ISSN 1469-493X. PMC 6984636. PMID 31930781.
- ↑ Pediani JD, Ward RJ, Godin AG, Marsango S, Milligan G (June 2016). "Dynamic Regulation of Quaternary Organization of the M1 Muscarinic Receptor by Subtype-selective Antagonist Drugs". The Journal of Biological Chemistry. 291 (25): 13132–46. doi:10.1074/jbc.M115.712562. PMC 4933229. PMID 27080256.